Filgrastim (Granix, Neupogen, Nivestym) — 2026 Medicare Part D coverage
filgrastim — sold as Granix, Neupogen, Nivestym, Releuko, Zarxio: 15 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover filgrastim?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| Nivestym 300 MCG in 0.5 ML Prefilled Syringe brand · RxCUI 2057205 | 176 (54%) | 5 | 135 | 0 | 0 |
| Nivestym 480 MCG in 0.8 ML Prefilled Syringe brand · RxCUI 2057216 | 176 (54%) | 5 | 135 | 0 | 0 |
| Nivestym 300 MCG in 1 ML Injection brand · RxCUI 2057212 | 175 (53%) | 5 | 134 | 0 | 0 |
| Nivestym 480 MCG in 1.6 ML Injection brand · RxCUI 2057219 | 175 (53%) | 5 | 134 | 0 | 0 |
| Zarxio 300 MCG in 0.5 ML Prefilled Syringe brand · RxCUI 1605071 | 166 (51%) | 5 | 121 | 0 | 0 |
| Zarxio 480 MCG in 0.8 ML Prefilled Syringe brand · RxCUI 1605075 | 166 (51%) | 5 | 121 | 0 | 0 |
| Granix 300 MCG in 1 ML Injection brand · RxCUI 2101459 | 60 (18%) | 5 | 56 | 1 | 0 |
| Granix 300 MCG in 0.5 ML Prefilled Syringe brand · RxCUI 1442681 | 57 (17%) | 5 | 53 | 1 | 0 |
| Granix 480 MCG in 0.8 ML Prefilled Syringe brand · RxCUI 1442683 | 57 (17%) | 5 | 53 | 1 | 0 |
| Releuko 300 MCG in 0.5 ML Prefilled Syringe brand · RxCUI 2595950 | 28 (9%) | 4 | 24 | 0 | 0 |
| Releuko 480 MCG in 0.8 ML Prefilled Syringe brand · RxCUI 2595962 | 28 (9%) | 4 | 24 | 0 | 0 |
| Neupogen 300 MCG in 0.5 ML Prefilled Syringe brand · RxCUI 727537 | 14 (4%) | 5 | 10 | 1 | 0 |
| Neupogen 300 MCG in 1 ML Injection brand · RxCUI 1649946 | 14 (4%) | 5 | 10 | 1 | 0 |
| Neupogen 480 MCG in 0.8 ML Prefilled Syringe brand · RxCUI 727545 | 14 (4%) | 5 | 10 | 1 | 0 |
| Neupogen 480 MCG in 1.6 ML Injection brand · RxCUI 1649964 | 14 (4%) | 5 | 10 | 1 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.